{
  "paper_id": "PMC5854749",
  "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5854749/",
  "figures": {
    "figure_1": {
      "figure_number": "Figure 1",
      "title": "Fig. 1.",
      "caption": "Citation disposition for the literature search",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f39/5854749/3ff6c0947462/40265_2018_881_Fig1_HTML.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f39/5854749/3ff6c0947462/40265_2018_881_Fig1_HTML.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f39/5854749/3ff6c0947462/40265_2018_881_Fig1_HTML.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f39/5854749/3ff6c0947462/40265_2018_881_Fig1_HTML.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "Fig1",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f39/5854749/3ff6c0947462/40265_2018_881_Fig1_HTML.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC5854749/images/figure_1.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f39/5854749/3ff6c0947462/40265_2018_881_Fig1_HTML.jpg"
    },
    "figure_2": {
      "figure_number": "Figure 2",
      "title": "Fig. 2.",
      "caption": "Growth in publications related to biosimilar switching, from 1993 to 2016",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f39/5854749/23fa4636565e/40265_2018_881_Fig2_HTML.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f39/5854749/23fa4636565e/40265_2018_881_Fig2_HTML.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f39/5854749/23fa4636565e/40265_2018_881_Fig2_HTML.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f39/5854749/23fa4636565e/40265_2018_881_Fig2_HTML.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "Fig2",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f39/5854749/23fa4636565e/40265_2018_881_Fig2_HTML.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC5854749/images/figure_2.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f39/5854749/23fa4636565e/40265_2018_881_Fig2_HTML.jpg"
    },
    "figure_3": {
      "figure_number": "Figure 3",
      "title": "Fig. 3.",
      "caption": "Types of study designs across larger and smaller biologics. Biosimilars of adalimumab, etanercept, and rituximab were approved as of the cut-off date for manuscript. However, there was likely insufficient time for completion and publication of RWE with etanercept and rituximab, and a biosimilar adalimumab was not marketed as of the cut-off date. RCT randomized clinical trial, RWE real world evidence, rHuEPO recombinant human erythropoietin, GH growth hormone",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f39/5854749/f72234c253b0/40265_2018_881_Fig3_HTML.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f39/5854749/f72234c253b0/40265_2018_881_Fig3_HTML.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f39/5854749/f72234c253b0/40265_2018_881_Fig3_HTML.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f39/5854749/f72234c253b0/40265_2018_881_Fig3_HTML.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "Fig3",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f39/5854749/f72234c253b0/40265_2018_881_Fig3_HTML.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC5854749/images/figure_3.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f39/5854749/f72234c253b0/40265_2018_881_Fig3_HTML.jpg"
    },
    "figure_4": {
      "figure_number": "Figure 4",
      "title": "Fig. 4.",
      "caption": "Switching study design for biosimilar filgrastim (EP2006) versus reference medicine. d day, DSN duration of severe neutropenia",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f39/5854749/0e828c87b8d0/40265_2018_881_Fig4_HTML.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f39/5854749/0e828c87b8d0/40265_2018_881_Fig4_HTML.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f39/5854749/0e828c87b8d0/40265_2018_881_Fig4_HTML.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f39/5854749/0e828c87b8d0/40265_2018_881_Fig4_HTML.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "Fig4",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f39/5854749/0e828c87b8d0/40265_2018_881_Fig4_HTML.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC5854749/images/figure_4.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f39/5854749/0e828c87b8d0/40265_2018_881_Fig4_HTML.jpg"
    },
    "figure_5": {
      "figure_number": "Figure 5",
      "title": "Fig. 5.",
      "caption": "Switching study design for biosimilar etanercept (GP2015) versus reference medicine. wk week",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f39/5854749/71f8f861ab2d/40265_2018_881_Fig5_HTML.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f39/5854749/71f8f861ab2d/40265_2018_881_Fig5_HTML.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f39/5854749/71f8f861ab2d/40265_2018_881_Fig5_HTML.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f39/5854749/71f8f861ab2d/40265_2018_881_Fig5_HTML.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "Fig5",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f39/5854749/71f8f861ab2d/40265_2018_881_Fig5_HTML.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC5854749/images/figure_5.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f39/5854749/71f8f861ab2d/40265_2018_881_Fig5_HTML.jpg"
    }
  },
  "claims": [
    {
      "sentence": "Figure 1 describes the step-by-step citation disposition.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "As shown in Fig. 1, after applying the exclusion criteria, 1,127 citations remained for the abstract screening step.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "There has been a steady growth in this literature from 1993 to the present with rapid growth in 2015 and 2016 (Fig. 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Both RCTs and RWE are available in the literature with information on switching from reference medicines to their corresponding biosimilar (Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "In support of their biosimilar filgrastim registration, the sponsor conducted a clinical safety and efficacy study that incorporated five switchover events (Fig. 4), comparing 107 breast cancer patients that had been switched with 51 patients that had been treated continuously with either the reference medicine or the biosimilar [28].",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nSwitching study design for biosimilar filgrastim (EP2006) versus reference medicine. d day, DSN duration of severe neutropeniaA cross-over study design incorporating three switchover events (Fig. 5) was incorporated into the clinical safety and efficacy study that supported licensure of a biosimilar etanercept, GP2015 [24].",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Figure 1 describes the step-by-step citation disposition.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "As shown in Fig. 1, after applying the exclusion criteria, 1,127 citations remained for the abstract screening step.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "There has been a steady growth in this literature from 1993 to the present with rapid growth in 2015 and 2016 (Fig. 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Both RCTs and RWE are available in the literature with information on switching from reference medicines to their corresponding biosimilar (Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "In support of their biosimilar filgrastim registration, the sponsor conducted a clinical safety and efficacy study that incorporated five switchover events (Fig. 4), comparing 107 breast cancer patients that had been switched with 51 patients that had been treated continuously with either the reference medicine or the biosimilar [28].",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nSwitching study design for biosimilar filgrastim (EP2006) versus reference medicine. d day, DSN duration of severe neutropeniaA cross-over study design incorporating three switchover events (Fig. 5) was incorporated into the clinical safety and efficacy study that supported licensure of a biosimilar etanercept, GP2015 [24].",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Figure 1 describes the step-by-step citation disposition.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "As shown in Fig. 1, after applying the exclusion criteria, 1,127 citations remained for the abstract screening step.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "There has been a steady growth in this literature from 1993 to the present with rapid growth in 2015 and 2016 (Fig. 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Both RCTs and RWE are available in the literature with information on switching from reference medicines to their corresponding biosimilar (Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "In support of their biosimilar filgrastim registration, the sponsor conducted a clinical safety and efficacy study that incorporated five switchover events (Fig. 4), comparing 107 breast cancer patients that had been switched with 51 patients that had been treated continuously with either the reference medicine or the biosimilar [28].",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nSwitching study design for biosimilar filgrastim (EP2006) versus reference medicine. d day, DSN duration of severe neutropeniaA cross-over study design incorporating three switchover events (Fig. 5) was incorporated into the clinical safety and efficacy study that supported licensure of a biosimilar etanercept, GP2015 [24].",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Figure 1 describes the step-by-step citation disposition.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "As shown in Fig. 1, after applying the exclusion criteria, 1,127 citations remained for the abstract screening step.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "There has been a steady growth in this literature from 1993 to the present with rapid growth in 2015 and 2016 (Fig. 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Both RCTs and RWE are available in the literature with information on switching from reference medicines to their corresponding biosimilar (Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "In support of their biosimilar filgrastim registration, the sponsor conducted a clinical safety and efficacy study that incorporated five switchover events (Fig. 4), comparing 107 breast cancer patients that had been switched with 51 patients that had been treated continuously with either the reference medicine or the biosimilar [28].",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nSwitching study design for biosimilar filgrastim (EP2006) versus reference medicine. d day, DSN duration of severe neutropeniaA cross-over study design incorporating three switchover events (Fig. 5) was incorporated into the clinical safety and efficacy study that supported licensure of a biosimilar etanercept, GP2015 [24].",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Figure 1 describes the step-by-step citation disposition.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "As shown in Fig. 1, after applying the exclusion criteria, 1,127 citations remained for the abstract screening step.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "There has been a steady growth in this literature from 1993 to the present with rapid growth in 2015 and 2016 (Fig. 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Both RCTs and RWE are available in the literature with information on switching from reference medicines to their corresponding biosimilar (Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "In support of their biosimilar filgrastim registration, the sponsor conducted a clinical safety and efficacy study that incorporated five switchover events (Fig. 4), comparing 107 breast cancer patients that had been switched with 51 patients that had been treated continuously with either the reference medicine or the biosimilar [28].",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nSwitching study design for biosimilar filgrastim (EP2006) versus reference medicine. d day, DSN duration of severe neutropeniaA cross-over study design incorporating three switchover events (Fig. 5) was incorporated into the clinical safety and efficacy study that supported licensure of a biosimilar etanercept, GP2015 [24].",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Figure 1 describes the step-by-step citation disposition.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "As shown in Fig. 1, after applying the exclusion criteria, 1,127 citations remained for the abstract screening step.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "There has been a steady growth in this literature from 1993 to the present with rapid growth in 2015 and 2016 (Fig. 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Both RCTs and RWE are available in the literature with information on switching from reference medicines to their corresponding biosimilar (Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "In support of their biosimilar filgrastim registration, the sponsor conducted a clinical safety and efficacy study that incorporated five switchover events (Fig. 4), comparing 107 breast cancer patients that had been switched with 51 patients that had been treated continuously with either the reference medicine or the biosimilar [28].",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nSwitching study design for biosimilar filgrastim (EP2006) versus reference medicine. d day, DSN duration of severe neutropeniaA cross-over study design incorporating three switchover events (Fig. 5) was incorporated into the clinical safety and efficacy study that supported licensure of a biosimilar etanercept, GP2015 [24].",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Figure 1 describes the step-by-step citation disposition.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "As shown in Fig. 1, after applying the exclusion criteria, 1,127 citations remained for the abstract screening step.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "There has been a steady growth in this literature from 1993 to the present with rapid growth in 2015 and 2016 (Fig. 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Both RCTs and RWE are available in the literature with information on switching from reference medicines to their corresponding biosimilar (Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "In support of their biosimilar filgrastim registration, the sponsor conducted a clinical safety and efficacy study that incorporated five switchover events (Fig. 4), comparing 107 breast cancer patients that had been switched with 51 patients that had been treated continuously with either the reference medicine or the biosimilar [28].",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nSwitching study design for biosimilar filgrastim (EP2006) versus reference medicine. d day, DSN duration of severe neutropeniaA cross-over study design incorporating three switchover events (Fig. 5) was incorporated into the clinical safety and efficacy study that supported licensure of a biosimilar etanercept, GP2015 [24].",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Figure 1 describes the step-by-step citation disposition.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "As shown in Fig. 1, after applying the exclusion criteria, 1,127 citations remained for the abstract screening step.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "There has been a steady growth in this literature from 1993 to the present with rapid growth in 2015 and 2016 (Fig. 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Both RCTs and RWE are available in the literature with information on switching from reference medicines to their corresponding biosimilar (Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "In support of their biosimilar filgrastim registration, the sponsor conducted a clinical safety and efficacy study that incorporated five switchover events (Fig. 4), comparing 107 breast cancer patients that had been switched with 51 patients that had been treated continuously with either the reference medicine or the biosimilar [28].",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nSwitching study design for biosimilar filgrastim (EP2006) versus reference medicine. d day, DSN duration of severe neutropeniaA cross-over study design incorporating three switchover events (Fig. 5) was incorporated into the clinical safety and efficacy study that supported licensure of a biosimilar etanercept, GP2015 [24].",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Figure 1 describes the step-by-step citation disposition.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Figure 1 describes the step-by-step citation disposition.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Figure 1 describes the step-by-step citation disposition.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "As shown in Fig. 1, after applying the exclusion criteria, 1,127 citations remained for the abstract screening step.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "There has been a steady growth in this literature from 1993 to the present with rapid growth in 2015 and 2016 (Fig. 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Both RCTs and RWE are available in the literature with information on switching from reference medicines to their corresponding biosimilar (Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "In support of their biosimilar filgrastim registration, the sponsor conducted a clinical safety and efficacy study that incorporated five switchover events (Fig. 4), comparing 107 breast cancer patients that had been switched with 51 patients that had been treated continuously with either the reference medicine or the biosimilar [28].",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nSwitching study design for biosimilar filgrastim (EP2006) versus reference medicine. d day, DSN duration of severe neutropeniaA cross-over study design incorporating three switchover events (Fig. 5) was incorporated into the clinical safety and efficacy study that supported licensure of a biosimilar etanercept, GP2015 [24].",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "As shown in Fig. 1, after applying the exclusion criteria, 1,127 citations remained for the abstract screening step.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "There has been a steady growth in this literature from 1993 to the present with rapid growth in 2015 and 2016 (Fig. 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Both RCTs and RWE are available in the literature with information on switching from reference medicines to their corresponding biosimilar (Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "In support of their biosimilar filgrastim registration, the sponsor conducted a clinical safety and efficacy study that incorporated five switchover events (Fig. 4), comparing 107 breast cancer patients that had been switched with 51 patients that had been treated continuously with either the reference medicine or the biosimilar [28].",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nSwitching study design for biosimilar filgrastim (EP2006) versus reference medicine. d day, DSN duration of severe neutropeniaA cross-over study design incorporating three switchover events (Fig. 5) was incorporated into the clinical safety and efficacy study that supported licensure of a biosimilar etanercept, GP2015 [24].",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "In support of their biosimilar filgrastim registration, the sponsor conducted a clinical safety and efficacy study that incorporated five switchover events (Fig. 4), comparing 107 breast cancer patients that had been switched with 51 patients that had been treated continuously with either the reference medicine or the biosimilar [28].",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "A cross-over study design incorporating three switchover events (Fig. 5) was incorporated into the clinical safety and efficacy study that supported licensure of a biosimilar etanercept, GP2015 [24].",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    }
  ],
  "extraction_stats": {
    "figures_count": 5,
    "claims_count": 63,
    "images_downloaded": 5,
    "tables_filtered": 75
  }
}